GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 177 filers reported holding GENMAB A/S in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,406 | -7.2% | 39,864 | 0.0% | 0.01% | -10.0% |
| Q2 2023 | $1,515 | +161.2% | 39,864 | +159.5% | 0.01% | +150.0% |
| Q1 2023 | $580 | -13.3% | 15,362 | -2.8% | 0.00% | -20.0% |
| Q4 2022 | $669 | -99.9% | 15,797 | 0.0% | 0.01% | +25.0% |
| Q3 2022 | $508,000 | -77.6% | 15,797 | -77.3% | 0.00% | -76.5% |
| Q2 2022 | $2,264,000 | -10.2% | 69,675 | 0.0% | 0.02% | +13.3% |
| Q1 2022 | $2,521,000 | -9.2% | 69,675 | 0.0% | 0.02% | +7.1% |
| Q4 2021 | $2,777,000 | +60.1% | 69,675 | +75.5% | 0.01% | +40.0% |
| Q3 2021 | $1,735,000 | +7.0% | 39,701 | 0.0% | 0.01% | 0.0% |
| Q2 2021 | $1,621,000 | +5.7% | 39,701 | -15.0% | 0.01% | 0.0% |
| Q1 2021 | $1,533,000 | -19.3% | 46,700 | 0.0% | 0.01% | -23.1% |
| Q4 2020 | $1,899,000 | +6.9% | 46,700 | -3.7% | 0.01% | 0.0% |
| Q3 2020 | $1,776,000 | -14.9% | 48,500 | -21.3% | 0.01% | -23.5% |
| Q2 2020 | $2,088,000 | +40.6% | 61,600 | -12.1% | 0.02% | +112.5% |
| Q1 2020 | $1,485,000 | – | 70,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |